Industry watchers were worried about neglect for Bayer’s healthcare division when the company chased down its megamerger with agrochemical giant Monsanto. But that deal hasn’t even closed yet, and healthcare sales are already showing cause for concern. More: Turns out,
read moreAs opioid scrutiny intensifies around the country, Mallinckrodt has received another subpoena seeking information about its sales of the powerful painkillers. More: Mallinckrodt subpoenaed, again, over sales of oxymorphone in growing opioid crisis Source: fierce
read moreThe day of judgment is near for Martin Shkreli, whose lawyer admits became “the most hated man in America.” Shkreli has told a court he is misunderstood and deserves leniency—no more than 18 months in jail. However, a ruling this
read moreCompanies expecting competition from Celgene multiple sclerosis candidate ozanimod just got a reprieve. The big biotech revealed late Tuesday that the FDA refused to accept its approval application because of “incomplete” pharmacology data. And that means more time for its
read moreCities and counties have been at the forefront of litigation against opioid makers, seeking to hold pharma companies accountable for their spending on the addiction epidemic. Now the feds are getting involved. More: Justice Department steps in to back hundreds
read moreNovo Nordisk has filed regulatory applications in the US and European Union seeking approval to market N8-GP for the treatment of haemophilia More: Novo files N8-GP in the US and EU Source: News
read more© 1994 - 2024 B.M. Pharmaceuticals